HCPCS Level II Q5132: Adalimumab-afzb (Abrilada) 10 mg Injection
HCPCS Level II code Q5132 designates the 10 mg injection of adalimumab-afzb (Abrilada), a biosimilar to adalimumab used in outpatient biologic therapy. Its presence in the HCPCS Level II file enables facilities and clinicians to bill for the specific biosimilar product and supports product-level tracking, formulary management, and payer coverage determinations. Nationally, biosimilar codes like Q5132 matter for cost management and for monitoring uptake of lower-cost biologic alternatives.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find benchmarks and coverage context for billing Q5132, guidance on typical sites of service and service type, and a summary of common billing modifiers and reporting considerations. The publication also outlines clinical context for adalimumab biosimilars and how the HCPCS Level II designation affects coding workflows and payer adjudication. Data not available in the input is noted where applicable.
Sign up for hcpcs Q5132 policy alerts
Get alerted when payer policies referencing Q5132 are released or updated.
Billing Code Overview
HCPCS Level II code Q5132 represents an injection of adalimumab-afzb (Abrilada), a biosimilar formulation, in a 10 mg dosage. This code describes the drug administration item itself and is used for billing the specific biosimilar product rather than the reference biologic.
Service Type: Drug injection (biosimilar)
Typical Site of Service: Outpatient infusion/clinic, physician office, or other outpatient administration settings
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with an immune-mediated inflammatory disease such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or plaque psoriasis who requires subcutaneous biologic therapy. The patient presents to an infusion or injection clinic, specialty pharmacy clinic, or office-based procedure room for administration of a biosimilar adalimumab product. The service documented by Q5132 represents a 10 mg prefilled-syringe or pen dose of adalimumab-afzb (Abrilada) used for subcutaneous injection.
The clinical workflow includes verification of the medication order and dose, allergy and infection screening, patient education regarding self-administration if discharge to home is planned, preparation of the injection by a licensed clinician or trained staff, administration via subcutaneous injection, and post-injection observation for adverse reactions. Documentation includes medication lot and expiration, administration site, route, dose, informed consent or teaching, and any immediate adverse effects. Billing uses Q5132 to report the specific HCPCS Level II supply for the 10 mg adalimumab-afzb product when applicable per payer guidance.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased Procedural Services | Use when work required is substantially greater than typically required for administration-related services (rare for standard injections). |
23 | Unusual Anesthesia | Use if general or regional anesthesia is provided for an otherwise normally non-anesthetized procedure (unlikely for subcutaneous injection). |
52 | Reduced Services | Use when the service is partially reduced or eliminated at the physician's discretion. |
53 | Discontinued Procedure | Use when the procedure was started but discontinued due to extenuating circumstances. |
54 | Surgical Care Only | Use when only the intra-procedural surgical care is billed by a provider (rare for injectable biologics). |
55 | Post-Operative Management Only | Use when only post-operative care is billed by a provider. |
56 | Pre-Operative Management Only | Use when only pre-operative care is billed by a provider. |
62 | Two Surgeons | Use when two surgeons share the same operative session (not typically applicable to biologic injection). |
AS | Left Against Medical Advice | Use when a beneficiary leaves against medical advice during the encounter. |
CO | Casts Only | Use for cast-related services (rarely applicable; included if splinting/casting services occur in same visit). |
CQ | Service Delivered Under an Approved Plan | Use when a service is delivered under a clinical trial or approved study plan. |
FX | Single Physician Non-participating | Use to indicate first physician of a non-participating group when multiple physicians are involved. |
FY | First Radiology Group | Use to identify the first radiology group involved (not common for injections). |
QK | Medical Direction of Two or More Anesthetists | Use when medically directing multiple anesthetists (not typical for this service). |
QX | CRNA Service - With Medical Direction by a Physician | Use to indicate CRNA service with physician direction (not typical here). |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
207RC0000X | Rheumatology | Rheumatologists frequently prescribe and oversee biologic therapies such as adalimumab-afzb. |
2080P0207X | Allergy & Immunology | Allergists/immunologists manage biologic therapies for certain immune-mediated conditions. |
363L00000X | Nurse Practitioner | Nurse practitioners in specialty clinics often perform patient education and injections. |
363A00000X | Physician Assistant | PAs commonly administer biologic injections and document clinical encounters. |
207L00000X | Internal Medicine | Internists manage chronic inflammatory diseases and coordinate biologic therapy. |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
M06.9 | Rheumatoid arthritis, unspecified | Rheumatoid arthritis is a common indication for adalimumab therapy. |
L40.0 | Psoriasis vulgaris | Moderate to severe plaque psoriasis is an approved indication for adalimumab biologics. |
M07.0 | Distal interphalangeal psoriatic arthropathy | Psoriatic arthritis presentations commonly treated with TNF inhibitors. |
M45.9 | Ankylosing spondylitis, unspecified | Ankylosing spondylitis is an inflammatory spondyloarthropathy treated with tumor necrosis factor inhibitors. |
K50.90 | Crohn's disease, unspecified, without complications | Moderate to severe Crohn disease can be treated with anti-TNF agents including adalimumab. |
K51.90 | Ulcerative colitis, unspecified, without complications | Moderate to severe ulcerative colitis is another indication for biologic anti-TNF therapy. |
H61.23 | Impacted cerumen, bilateral | Data not relevant; not used for biologic therapy billing. |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
96372 | Therapeutic, prophylactic, or diagnostic injection (subcutaneous or intramuscular) | Common code for administration of a subcutaneous medication when a separate administration fee is billed alongside the drug HCPCS code. |
99001 | Handling and/or conveyance of diagnostic specimens (clinical lab procedures) (Note: some payers have specific codes for medication handling) | May be used by some facilities for special handling or preparation services related to biologic agents per payer rules. |
99070 | Supplies and materials (except spectacles) provided by the physician over and above those usually included with the office visit | Used to report disposable supplies associated with injection administration when payer allows. |
96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | Not typical for subcutaneous injection, included when infusion services occur in the same visit. |
99406 | Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minutes up to 10 minutes | Example of an ancillary counseling CPT that may be provided during a medication management visit (billing depends on documentation and payer policy). |